ANI Pharmaceuticals (NASDAQ:ANIP) Insider Christopher Mutz Sells 5,323 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Christopher Mutz sold 5,323 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $78.02, for a total value of $415,300.46. Following the completion of the transaction, the insider directly owned 84,840 shares of the company’s stock, valued at approximately $6,619,216.80. The trade was a 5.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $75.10 on Tuesday. The business has a 50 day moving average of $80.69 and a 200-day moving average of $86.64. The company has a market capitalization of $1.69 billion, a P/E ratio of 46.07 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a 1 year low of $54.10 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ANIP. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC bought a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $2,706,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 510 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ANIP shares. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Barclays started coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.